Immunotherapy has become a pivotal cancer treatment following surgery, radiotherapy, and chemotherapy, with the major form including adoptive cell therapy (ACT) and immune checkpoint blockade (ICB). But, in some patients with solid tumors, durable therapeutic efficacy remains elusive, which may owe to tumor immune evasion. The research reveals that VDAC2, as a relevant dual-function target of metabolism and immune escape, whose mechanism based on VDAC2-BAK axis and cGAS-STING signaling pathway, providing us a new idea for overcoming tumor immune escape.
Fu et al. (Wed,) studied this question.